Effectiveness and clinical response rates of a residential eating disorders facility.

The purpose of this study was to determine the effectiveness of a residential treatment program for adults and adolescents with eating disorders across a wide spectrum of measures. Data on body mass, eating disorder severity, depression, anxiety, and two measures of quality of life were collected on 139 consecutively admitted adolescents and 111 adults at a residential treatment program (N = 250). The same measures were completed at post-treatment.

Failure to feed patients with anorexia nervosa and other perils and perplexities in the medical care of eating disorder patients.

A 28 year old woman with anorexia nervosa was sent to an emergency room by her gastroenterologist for weakness and nausea following placement of a percutaneous endoscopic gastrostomy (PEG) tube, with a plan for admission to the hospital. She spent 2 days in the emergency room without receiving any nutrition, and was discharged home after being told that her laboratory tests and x-rays were normal. The following day, her gastroenterologist reviewed the x-rays and determined that she had a bowel obstruction, at which point she was admitted to the hospital, weighing 2 kg less than on her initial visit.

Psychopharmacologic treatment of obesity and eating disorders in children and adolescents.

This review discusses the evidence base for medications that are currently used for obesity and eating disorders, including their Food and Drug Administration approval status by disorder and age group, contraindications, and major adverse effects. Investigational agents currently being considered, issues related to psychiatric and medical comorbidity, limitations of pharmacologic strategies, and recommendations for treatment are also addressed.

Double-blind placebo-controlled trial of quetiapine in anorexia nervosa.

Objective: Our objective is to determine whether quetiapine was superior to placebo in increasing weight or reducing core symptoms of anorexia nervosa as assessed by the Yale-Brown-Cornell Eating Disorder Scale and the Eating Disorder Inventory-2.

Method: Participants were randomised to 8 weeks of quetiapine or placebo.

Results: There are 21 participants who signed informed consent, 15 were randomised, 14 returned for at least one visit after receiving drug and 10 completed the study.

Pharmacotherapy for eating disorders and obesity.

Anorexia nervosa and bulimia nervosa are significant mental health problems in the adolescent population; however, there are no medications approved by the FDA for the treatment of adolescents with either of these disorders. Many medications are used off label for both the symptoms of eating disorders and their co-morbid conditions, particularly SSRIs and atypical anti-psychotics. The dosing, side effect profile, and long term effects of these medications in children and adolescents is unclear.

Quetiapine in anorexia nervosa patients: an open label outpatient pilot study.

Objectives: The main objective of the study was to determine whether quetiapine was effective in reducing scores on the positive and negative syndrome scale (PANSS) in anorexia nervosa (AN) patients. Secondary objectives included determining whether quetiapine was effective in reducing symptoms of anxiety and depression. In addition, the effect on weight was determined.

Available pharmacological treatments for anorexia nervosa.

Currently, no medications are approved by the FDA for the treatment of anorexia nervosa (AN). However, there are several promising pharmacological targets. Treatment includes a weight restoration and a weight maintenance phase and different pharmacological treatments may be useful in one phase, but not the other.

Predictors of disordered eating in a sample of elite Division I college athletes.

Objective: The present study sought to investigate the relationship between a number of areas of elite student-athletes' lives and disordered eating.

Method: We surveyed 1445 elite Division I athletes at 11 different institutions and in 11 different sports. Hierarchical regression was used to indicate specific areas of the participants' collegiate experience that may be associated with disordered eating attitudes and symptomatology.

Olanzapine in the treatment of anorexia nervosa: an open label trial.

Objective: The primary goal of the study was to determine if olanzapine is effective in producing weight gain in patients with anorexia nervosa.

Method: Twenty patients with anorexia nervosa (restricting or binge/purge subtype) without schizophrenia, schizoaffective disorder, or bipolar disorder enrolled in an open label study of olanzapine 10 mg. Patients attended weekly drug monitoring sessions and weekly group medication adherence sessions that provided psychoeducation.

Childhood and adolescent anorexia nervosa.

Eating disorders are common during childhood and adolescence. Early intervention is associated with the best prognosis. Treatment interventions that focus on achieving ideal body weight and use various family therapy approaches are most likely to be effective.

Eating disorders: a guide for the primary care physician.

The diagnostic criteria for eating disorders are described, including assessment of complications related to semi-starvation, binge eating, and purging. The key components of treatment are presented, including normalization of eating, individual and family therapy, and cognitive behavioral therapy. The role of the primary care physician in diagnosis and treatment is outlined.